RESEARCHER PROFILE

Frank Stephen Hodi

← Back to Harvard University

F

Harvard University

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and ManagementMelanoma and MAPK PathwaysT-cell and B-cell Immunology

Frank Stephen Hodi works in Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, T-cell and B-cell Immunology. Recorded institutional associations include Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center.

1,583Publications
163,538Citations
155H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

    2010 · 15,151 citations
  2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

    2012 · 12,603 citations
  3. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

    2015 · 8,134 citations
  4. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    2017 · 5,342 citations
  5. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    2014 · 5,222 citations
  6. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    2019 · 3,703 citations
  7. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    2013 · 3,392 citations
  8. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

    2009 · 3,222 citations
  9. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

    2015 · 2,784 citations
  10. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

    2015 · 2,676 citations
  11. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

    2017 · 2,464 citations
  12. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

    2017 · 2,379 citations
  13. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    2014 · 2,218 citations
  14. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    2015 · 2,139 citations
  15. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

    2019 · 2,063 citations
  16. RECIST 1.1—Update and clarification: From the RECIST committee

    2016 · 1,895 citations
  17. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

    2014 · 1,771 citations
  18. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

    2016 · 1,577 citations
  19. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    2015 · 1,572 citations
  20. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

    2017 · 1,516 citations
  21. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

    2018 · 1,416 citations
  22. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

    2018 · 1,395 citations
  23. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

    2018 · 1,321 citations
  24. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    2016 · 1,318 citations
  25. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

    2018 · 1,238 citations

← Return to the university profile